The improved factor concentrate

Hamostaseologie

Volumn 29, Issue 1, 2009, Pages

  Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Coagulation concentrates; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HYBRID PROTEIN;

BIOSYNTHESIS; BLEEDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; HEALTH CARE QUALITY; HEMOPHILIA; HUMAN; IMMUNOGENICITY; SHORT SURVEY;

EID: 59649114382     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616944     Document Type: Short Survey

References (15)

1. Barrow RT, Healey JF, Gailani D et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-568.
2. Gale AJ, Radtke KP, Cunningham MA et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4: 1315-1322.
3. Hough C, Lillicrap D. Gene therapy for hemophilia: an imperative to succeed. J Thromb Haemost 2005; 3: 1195-1205.
4. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-448.
5. Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
6. Lenting PJ, Van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-1360.
7. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
8. Pierce GF, Lillicrap D, Pipe SW, VandenDriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5: 901-906.
9. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3: 1692-1701.
10. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
11. Powell JS, Nugent DJ, Harrison JA et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-283.
12. Radtke KP, Griffin JH, Riceberg J, Gale AJ. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. J Thromb Haemost 2007; 5: 102-108.
13. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.
14. Sarafanov AG, Makogonenko EM, Andersen OM et al. Localization of the low-density lipoprotein receptor-related protein regions involved in binding to the A2 domain of coagulation factor VIII. Thromb Haemost 2007; 98: 1170-1181.
15. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-3673.